Processa Pharmaceuticals (PCSA) EBT (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported EBT for 15 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 40.69% year-over-year to -$2.3 million; the trailing twelve-month figure through Jun 2026 stood at -$12.9 million (down 1.96% YoY), and the FY2025 full-year result was -$13.6 million, down 14.46% from the prior year.
• EBT grew to -$2.3 million in Q2 2026 per PCSA's latest filing, from -$3.4 million in the prior quarter.
• Across five years, EBT topped out at -$2.1 million in Q3 2023 and bottomed at -$13.0 million in Q4 2022.
• Historically, EBT has averaged -$3.9 million across 5 years, with a median of -$3.3 million in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT tumbled 286.63% in 2022, then surged 81.52% in 2023.
• Over 5 years, EBT stood at -$13.0 million in 2022, then soared by 81.52% to -$2.4 million in 2023, then retreated by 3.81% to -$2.5 million in 2024, then slumped by 48.28% to -$3.7 million in 2025, then surged by 36.84% to -$2.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$2.3 million, -$3.4 million, and -$3.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.